Excler JL,Pitisuttithum P. HIV Vaccine Development in Asia. In: Narain JP, editor. Three decades of HIV/AIDS in Asia. 1st ed. New Delhi: SAGE Publications India Pvt Ltd; 2012. P. 364-386.

Luvira V, Chamnanchanunt S, Bussaratid V, Leaungwutiwong P, Pitisuttithum P. Seroprevalence of Latent Cytomegalovirus Infection among Elderly Thais. Southeast Asian J Trop Med Public Health. 2012 Nov; 43(6):1419-25.

Bodhidatta L, Pitisuttithum P, Chamnanchanant S, Chang KT, Islam D, Bussaratid V, Venkatesan MM, Hale TL, Mason CJ. Establishment of a Shigella sonnei human challenge model in Thailand. Vaccine. 2012 Nov 19;30(49):7040-5.

Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, Koup RA, Madnote S, Arworn D, Shen X, Tomaras GD, Currier JR, Jiang M, Magaret C, Andrews C, Gottardo R, Gilbert P, Cardozo TJ, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Paris R, Greene K, Gao H, Gurunathan S, Tartaglia J, Sinangil F, Korber BT, Montefiori DC, Mascola JR, Robb ML, Haynes BF, Ngauy V, Michael NL, Kim JH, de Souza For The Moph Taveg Collaboration MS. The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120. AIDS Res Hum Retroviruses. 2012 Nov;28(11):1444-57.

Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang KK, Gilbert PB, Huang Y, Gurley TC, Kozink DM, Marshall DJ, Whitesides JF, Tsao CY, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Kim JH, Michael NL, Tomaras GD, Montefiori DC, Lewis GK, DeVico A, Evans DT, Ferrari G, Liao HX, Haynes BF. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol. 2012 Nov;86(21):11521-32.

Liao L, Bonsignori M, Hwang K, Moody AM, Park R, Crawford S, Chen H, Jeffries TL, Cooper M, Lu X, De R, Karasavvas N, Rerks-Ngarm S, Nitayaphan S, Kaewkungwal J, Tovanabutra S, Pitisuttithum P, Tartaglia J, Sinangil F, Kim J, Michael NL, Tomaras GD, Yang Z, Dai K, Pancera M, Nabel GJ, Mascola JR, Kwong PD, Pinter A, Zolla-Pazner S, Alam MS, Haynes BF. Design of an HIV Env Antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes within V1/V2 (Abstract). AIDS VACCINE 2012, Boston, USA, Sep 9-12, 2012 p.69.

Pollara J, Bonsignori M, Moody M, Alam M, Liao H, Hwang K, Pickeral J, Kappes J, Ochsenbauer c, Soderberg K, Gurley TC, Kozink DM, Marshall DJ, Whitesdies JF, Montefiori D, Robinson JE, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Kim J, Michael N, Tomaras G, Haynes BF, Ferrari G. Vaccine-induced ADCC-Mediating antibodies target unique and overlapping envelope epitopes (Abstract). AIDS VACCINE 2012, Boston, USA, Sep 9-12, 2012 p.73.

Bonsignori M, Pollara J, Moody MA, Kepler TB, Chen X, Gurley TC, Kozink DM, Marshall DJ, Whitesides JF, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Kim JH, Michael NL, Montefiori DC, Liao H, Ferrari G, Haynes BF. Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Preferentially Use the VH1 Gene Family (Abstract). AIDS VACCINE 2012, Boston, USA, Sep 9-12, 2012 p.134.

Htun WL, Bowonwatanuwong C, Phonrat B, Pitisuttithum P. Long Term Outcomes of Nevirapine Containing Antiretroviral Therapy at a Center in Thailand. Southeast Asian J Trop Med Public Health. 2012 July; 43(4):860-870.

Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, McLinden R, Tovanabutra S, Laurence-Chenine A, Sanders-Buell E, Moody MA, Bonsignori M, Ochsenbauer C, Kappes J, Tang H, Greene K, Gao H, Labranche CC, Andrews C, Polonis VR, Rerks-Ngarm S, Pitisuttithum P, et al. Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials. J Infect Dis. 2012 Aug 1;206(3):431-41.

Robb ML, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kunasol P, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis. 2012 May 29; 12: 531-37.

De Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, Valencia-Micolta A, Thelian D, Nitayaphan S, Pitisuttithum P, et al. The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope. J Immunol. 2012 May 15;188(10):5166-5176.

Matys K, Mallary S, Bautista O, Vuocolo S, Manalastas R, Pitisuttithum P, Saah A. Mother-infant transfer of anti-human papillomavirus (HPV) antibodies following vaccination with the quadrivalent HPV (type 6/11/16/18) virus-like particle vaccine. Clin Vaccine Immunol. 2012 Jun;19(6):881-5

Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012 Apr 5;366(14):1275-86.

Songthap A, Pitisuttithum P, Kaewkungwal J, Fungladda W, Bussaratid B. Knowledge, attitude, and acceptability of a human papiloma virus vaccine among students, parents and teachers in Thailand. Southeast Asian J Trop Med Public Health. 2012 Mar; 43(2):340-353.

Paris R, Bejrachandra S, Thongcharoen P, Nitayaphan S, Pitisuttithum P, Sambor A, Gurunathan S, Francis D, Ratto-Kim S, Karnasuta C, de Souza MS, Polonis VR, Brown AE, Kim JH, Stephens HA; for the Thai AIDS Vaccine Evaluation Group (Taveg). HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX(®) B/E. Vaccine. 2012 Jan 20;30(5):832-836.

Home